Anixa Biosciences (ANIX) to Release Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02.

Anixa Biosciences Trading Down 2.7 %

Shares of ANIX opened at $2.84 on Monday. The company’s fifty day simple moving average is $2.78 and its 200-day simple moving average is $3.03. The company has a market cap of $91.44 million, a P/E ratio of -7.28 and a beta of 0.86. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $4.20.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, February 18th.

Insider Activity

In related news, CEO Amit Kumar acquired 43,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was bought at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the acquisition, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at $1,248,632.75. This represents a 8.32 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the company’s stock in a transaction on Friday, January 17th. The stock was bought at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares in the company, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 75,289 shares of company stock valued at $177,021. 25.30% of the stock is currently owned by company insiders.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.